Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant. Science ShareTwitterFacebookXingLinkedin 5-hydroxytryptamine-3 receptor antagonistschemotherapy-induced nausea and vomitingfosnetupitantinjection site reactionsintravenous formulationnetupitantneurokinin-1 receptor antagonistspalonosetronprodrug You May Also Like Science 30. Januar 2023 Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Science 30. Januar 2023 Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Science 30. Januar 2023 The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.
